Stock Market News20 hours NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate Zacks
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
XIntellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
X